Imaging Endpoints

Join the Leaders in Oncology Imaging for an Exclusive Webinar! On October 16th at 2:00 PM ET, Imaging Endpoints and Fierce Bio are hosting a must-attend webinar: "How Does Imaging Support the Development of New Therapeutics? A Focus on ADC and Radioisotope Therapy." Discover how advanced imaging is playing a critical role in developing targeted cancer therapies like Antibody-Drug Conjugates (ADCs) and Radioisotope Therapy (RIT). With IE's extensive experience in clinical trials involving these therapies, we’ll share key insights into the significant impact of imaging for assessing the efficacy and safety of these treatments. What You’ll Learn: -Strategies for developing ADCs and RIT -The role of imaging in accelerating clinical trials and drug approval -Why protocol design and charter development are key for bridging the gap between early-phase trials and registration trials Expert Panel Includes: -Elliot K. Fishman, M.D. (Johns Hopkins), global leader in diagnostic and 3D imaging -Steven P. Rowe, M.D., Ph.D. (UNC School of Medicine, Molecular Imaging and Therapeutics Division Chief), expert in molecular imaging and theranostics -Daejin Abidoye, M.D. (Vice President, Head of Solid Tumors, AbbVie), research and development in leader and expert in antibody drug conjugate (ADC) technologies and immunotherapies -Ron Korn, M.D., Ph.D. (Imaging Endpoints), renown leader in clinical trial imaging Register now: https://lnkd.in/gEvVCTga #Webinar #ClinicalTrials #OncologyResearch #ImagingEndpoints #ADC #RadioisotopeTherapy #CancerTreatment

Join a Team That’s Leading the Way in Imaging for Oncology Trials! At Imaging Endpoints we're not just growing—we're thriving. As a global leader in imaging for oncology clinical trials, we offer a unique opportunity for professionals looking to make a real impact. Whether you're a seasoned expert or an emerging talent, this is your chance to work at the cutting edge of clinical research. Why Choose Imaging Endpoints? 🌟 Industry Leadership: Be part of a team that contributes to a 95% market authorization rate, driving innovation and excellence in oncology trials. 🤝 Collaborative Culture: We foster a supportive and dynamic work environment where your ideas matter. 📚 Continuous Growth: We prioritize learning and development, offering endless opportunities to expand your skills and career. 🖥 Advanced Technology: Work with the latest imaging technology that’s shaping the future of clinical trials. We believe in making a difference—and we’re looking for passionate professionals who share that vision. Ready to be part of a company that connects imaging to the cure? Visit our Careers Page and discover your next opportunity: 🔗 https://hubs.li/Q02SqqMR0 Know someone who might be a perfect fit? Share this post or tag them below—we’re excited to grow our team! #HiringNow #JoinOurTeam #ImagingEndpoints #iCRO #ImagingClinicalResearch #CareerOpportunities #OncologyCareers

Prostate cancer continues to be a pressing health issue, being the most common cancer among men and the second leading cause of cancer deaths. 🚨 Fortunately, advancements in imaging technologies like mpMRI and PSMA PET/CT (that Imaging Endpoints helped bring to market), are transforming how prostate cancer is diagnosed and staged. These innovations are not only enhancing clinical trials but also paving the way for better biomarker identification. However, the journey is not without challenges, particularly in standardizing and implementing these cutting-edge techniques effectively. As prostate cancer management evolves, clinical trials play a crucial role in evaluating new treatments and their effectiveness. The integration of PCWG3 and RECIST 1.1 is essential in clinical trials to accurately measure treatment responses and disease progression. These criteria help evaluate outcomes like metastasis-free survival, which can serve as a valid surrogate for overall survival in localized advanced prostate cancer. With the anticipated inclusion of PSMA-PET in the upcoming PCWG4 criteria, we expect improvement in the assessment of treatment efficacy. Enhanced imaging capabilities provided by mpMRI and PSMA-PET not only improve detection rates but also facilitate better evaluation of outcomes, ensuring that clinical trials yield meaningful data to guide future therapies. At Imaging Endpoints we pride ourselves on being at the forefront of designing imaging protocols for clinical trials in prostate cancer and have supported numerous recent regulatory approvals. 🤝 By collaborating closely with scientists, investigators, and radiologists, we ensure that our approaches reflect the latest innovations in imaging technology. Our commitment to excellence is evidenced by our perfect inspection record and industry-leading marketing authorization success rate. If you're looking to enhance your clinical trial outcomes, reach out to us at https://hubs.li/Q02RDxdm0 to discuss tailored imaging solutions! #ProstateCancer #MedicalImaging #ClinicalTrials #ImagingEndpoints #mpMRI #PSMAPET

At Imaging Endpoints we are dedicated to harnessing the power of medical imaging to revolutionize health care and save lives. We are currently seeking passionate Clinical Project Coordinator with at least 2 years of prior experience to join our team of innovators who are working tirelessly to “Connect Imaging to the Cure”. Apply here https://hubs.ly/Q02QWJT90 to learn more about joining our diverse, industry-leading team of imaging experts who are committed to fostering a culture of innovation, collaboration, and excellence. We offer competitive compensation packages, opportunities for professional growth, and the chance to work alongside a team of passionate individuals who are dedicated to making a positive impact on the lives of the patients around the world. “We look forward to you joining our global imaging operations team. As we continue to engage the industry’s top talent, we invite you to apply today to learn more about a thriving career as a Clinical Project Coordinator at Imaging Endpoints!” – Akila Rajagopal, Exec. Dir, Imaging Operations #ImagingEndpoints #ClinicalProjectCoordinator #Hiring

The landscape of lymphoma treatment is evolving with the integration of advanced imaging biomarkers, enhancing how we assess therapy responses. Lymphomas, including non-Hodgkin and Hodgkin types, are significant blood cancers with increasing incidence globally. Traditional size-based imaging methods often fall short in evaluating treatment efficacy, prompting a shift towards more sophisticated imaging techniques. Functional imaging, particularly 18F-FDG PET/CT, is revolutionizing our approach. By measuring metabolic activity rather than just size, it provides deeper insights into tumor response assessments. With superior sensitivity and specificity compared to traditional CT, methods like the Deauville 5-point scale in Lugano criteria are improving patient management decisions. Furthermore, innovative approaches like DWI and PET/MRI are paving the way for more accurate assessments of nodal involvement and tumor microenvironments. Bone marrow biopsies continue to play a crucial role alongside advanced imaging when it comes to response assessments. Clinical trials utilizing PET/CT are critical for standardizing response criteria and enhancing treatment evaluations. Reach out to us at https://hubs.li/Q02QttZN0 to connect with our experienced medical and scientific team that specializes in optimizing imaging charter and explore how our tailored imaging solutions can support your Lymphoma clinical trials. #Lymphoma #ImagingBiomarkers #PETCT #ImagingEndpoints #ClinicalTrials #MedicalImaging #Oncology

🚀 Elevate Your Clinical Trial with Imaging Endpoints’ Customized Proposal 🚀 At Imaging Endpoints we pride ourselves on delivering proposals that are truly customized to meet the unique needs of each sponsor’s trial, providing a road map to success. Our approach ensures transparency, thoroughness, and a proven track record, highlighted by a remarkable 95% market authorization rate for registration trials we support. Why Choose Us? • Tailored Solutions: Each proposal is meticulously crafted to address specific trial requirements, leveraging our deep expertise in clinical trial imaging to provide a road map to success. • Transparent Pricing: Our proposals feature clear, comprehensive pricing with no hidden costs, ensuring complete financial transparency. • Proven Success: With a flawless inspection record and over 150 successful marketing authorizations, our track record speaks for itself. • Collaborative Approach: Our medical, scientific, operations and regulatory experts strive to meet with your team to understand and explain imaging-specific protocol nuances, customizing our approach to better address your trials’ needs. Experience the Imaging Endpoints difference – where expertise meets excellence. Contact us today to learn how our customized proposals can support your clinical trials. Discover More at https://hubs.li/Q02Q5NBT0 📧 Reach out at experts@imagingendpoints.com to schedule a conversation with our business development team. #ClinicalTrials #Oncology #ImagingEndpoints #BusinessDevelopment #Innovation #Biopharma

Are you ready to unleash your creativity and expertise within our global Clinical Data Management team? We are seeking passionate Business Intelligence Developers to build data-driven innovations that support our team’s mission of "Connecting Imaging to the Cure™". This remarkable opportunity offers hands-on engagement in cultivating innovative data insights and advanced informatics solutions in support of oncology-focused medical imaging. “At Imaging Endpoints, we believe in empowering employees to push the boundaries of success where your ideas will directly shape the future of our cutting-edge informatics platform and data ecosystem. We are seeking the industry’s top talent to contribute to our team and drive transformative enterprise analytics. We invite you to explore this opportunity and begin an enriching journey with our team as a Business Intelligence Developer,” says Chris Diani, Senior Vice President of Data Management. Apply here https://hubs.li/Q02NY0Jy0 to learn more about how you can help us make a tremendous difference in the lives of patients around the world. #careers #hiring #businessintelligence

📢 Attending ESMO Congress? Stop by at Imaging Endpoints #ESMO booth #333! The Imaging Endpoints team is excited to share how our cutting-edge oncology trial solutions are helping to transform the clinical trials landscape. Don’t miss your chance to: ▫️ Learn about our groundbreaking technologies to enhance data quality and accuracy ▫️ Discover how Imaging Endpoints can streamline your oncology trials ▫️ Engage in discussions and network with industry key opinion leaders See you in Barcelona! Book your appointment with our CMO Dr. Korn ➡️ https://hubs.li/Q02Npcr00 #oncology #clinicaltrials #ESMO2024

🌟 Imaging is a cornerstone in the fight against lung cancer, a leading cause of cancer-related deaths worldwide. Low-dose computed tomography (CT) has transformed the landscape of early detection, drug development, and clinical trials. The integration of neoadjuvant therapy and imaging biomarkers is paving the way for innovative approaches in lung cancer clinical trials, making it an exciting time for research and development in this area. 📊 Lung cancer accounts for 14.3% of all cancers in men and 8.4% in women, primarily categorized into small-cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). NSCLC, making up over 85% of cases, is further classified based on histology and molecular features. Recent randomized trials exploring adjuvant immunotherapy and targeted therapies are reshaping the treatment landscape for resectable early-stage NSCLC. Personalized medicine, focusing on individual genetic profiles, is enhancing patient outcomes, particularly for those with high PD-L1 expression or specific genetic mutations. 🔍 Clinical trials have been using RECIST for registration purposes; however, PET/CT, which is often underutilized in this context, offers a more precise evaluation of metastatic lymph nodes and more effectively predicts disease progression and survival. Besides RECIST and iRECIST, metabolic response criteria, such as PERCIST and iPERCIST, leverage semi-quantitative parameters like SUVs, metabolic tumor volume, and total lesion glycolysis, serving as valuable assessment criteria and tools in clinical trial strategies. With a strong track record of improving trial outcomes by implementing the right strategy, our team specializes in optimizing imaging charter and assessment criteria for Lung Cancer clinical trials. Read complete article and reach out to us at https://hubs.li/Q02N0jfP0 #ImagingEndpoints #MedicalImaging #ClinicalTrials #Radiomics #OncologyResearch #LungCancer

Join us at #ESMO2024 (Barcelona, Spain, 13 to 16 September 2024), Europe's premier oncology conference, where Imaging Endpoints, the world's largest oncology-focused imaging CRO, will be showcasing its unparalleled expertise. Schedule time with our Chief Medical Officer, Dr. Ron Korn here https://hubs.li/Q02Mbfcm0